Sanja Tomovska
CEO Quant Biomarkers and Managing Partner Deep Knowledge Group
More than a decade of work as strategic development head for several large Swiss and international pharmaceutical corporations (Novartis, Abbott Life Sciences).
Dr. Tomovska has a vast amount of experience across pharmaceutical portfolio stages and business delivery: strategy, lifecycle, venture development, R&D, M&A, clinical, marketing, and change management. She holds a PhD in molecular biology from the University of Basel, Switzerland in Biomarkers in Cancer Diagnostics and has a business education from INSEAD and Columbia Business School.
Visit website: https://www.quant-biomarkers.com/#team
See also: Quant Biomarkers - Development and application of human biomarker panels and biological age metrics
Details last updated 14-Dec-2021
Sanja Tomovska News
Quant Biomarkers established to develop sophisticated analytical products
Quant Biomarkers - 10-Dec-2021
DKG subsidiary to introduce biomarker-driven Longevity risk mitigation and intervention support
Read more...